Drug
Fxs6837
Fxs6837: highest development phase Phase 3, developed by Shanghai Fosun Pharmaceutical. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FXS6837 Capsule NCT07747090 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| FXS6837 Capsule NCT07914894 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| FXS6837 Capsule NCT07750665 | Phase 2 | Primary IgAN |
Latest
No recent events.
Follow Fxs6837 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.